公开(公告)号：US20240148722A1

公开(公告)日：2024-05-09

申请号：US18546285

申请日：2022-02-20

Applicant: Biohaven Therapeutics Ltd.

Inventor： Randall J. BINDER ,  Marianne CARLSEN ,  Xiao JIN ,  Mark E. MCDONNELL ,  Allen B. REITZ ,  Camille REMEUR ,  Eric STROBEL ,  Huji TURDI

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/428 ,  A61K31/443 ,  A61K31/444 ,  A61K31/454 ,  A61K31/5377 ,  A61K38/06 ,  C07D213/74 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D451/04 ,  C07D487/04 ,  C07D495/04

CPC classification number: A61K31/496 ,  A61K31/415 ,  A61K31/428 ,  A61K31/443 ,  A61K31/444 ,  A61K31/454 ,  A61K31/5377 ,  A61K38/06 ,  C07D213/74 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D451/04 ,  C07D487/04 ,  C07D495/04

Abstract: The present invention relates to compounds that bind to TDP-43 and may have a therapeutic effect in treating a human disease, such as amyotrophic lateral sclerosis, frontotemporal lobar degeneration, hippocampal sclerosis of aging, chronic traumatic encephalopathy, inclusion body myositis, Alzheimer's disease, and/or Alzheimer's disease related disorders.

公开(公告)号：US20220388962A1

公开(公告)日：2022-12-08

申请号：US17635421

申请日：2020-08-21

Applicant: Biohaven Therapeutics Ltd.

Inventor： Marianne CARLSEN ,  Garry R. SMITH ,  Randall J. BINDER ,  Camille REMEUR ,  Allen B. REITZ ,  Xiao JIN

IPC: C07D215/42 ,  C07D401/12 ,  C07D215/46 ,  C07D487/04 ,  C07D401/10 ,  C07D471/04 ,  C07D487/10 ,  C07D401/14 ,  C07D413/12 ,  C07D405/12 ,  C07D401/04 ,  C07D405/04 ,  C07D413/14 ,  C07D491/056

Abstract: Pharmaceutical compositions of the invention comprise TDP-43 binding agents having a disease-modifying action in the treatment of diseases associated with TDP-43 that include ALS, FTLD, CTE, hippocampal sclerosis of aging (CARTS), Alzheimer's disease, and Alzheimer's disease related disorder, and disease that involve excess amounts of TDP-43 in the cytosol.